ChemLifeIntelCHEMICAL & LIFE SCIENCES INTELLIGENCE
Access
REGULATORY INTELLIGENCERecallNotable

Alchemee, LLC Initiates Class II Recall for Benzene-Contaminated Proactiv Skin Smoothing Exfoliator

PS
Priya SubramaniamView Profile →
Intelligence Analyst
EXECUTIVE SUMMARY

Alchemee, LLC has initiated a Class II recall for 3,500 bottles of Proactiv Skin Smoothing Exfoliator (Benzoyl Peroxide 2.5%) due to benzene contamination. This voluntary, nationwide recall highlights critical quality control gaps in topical drug manufacturing, demanding immediate action from procurement and regulatory teams to mitigate supply chain risks and protect brand integrity.

FDA Class II Recall: Benzene Contamination in Alchemee's Proactiv Exfoliator

Alchemee, LLC has initiated a Class II voluntary recall for 3,500 bottles of its Proactiv Skin Smoothing Exfoliator, a product containing Benzoyl Peroxide 2.5%. This critical action, designated recall number D-0360-2025, was prompted by the confirmed presence of benzene, a known human carcinogen, within the product. The recall was initiated by Alchemee, LLC on March 12, 2025, with the FDA classifying it as Class II on April 9, 2025. The affected product, distributed nationwide across the USA, includes specific packaging configurations: a 6 fl. oz. (177.4 mL) bottle with UPC 7 35786 01528 2, and a 0.33 OZ (9.45g) size with UPC 8 42944 10223 1. The specific lot identified is V4204A, with an expiration date of July 31, 2025. The recalling firm's address is 3 Skyline Dr, Hawthorne, NY 10532-2174, while the product is distributed by Alchemee, LLC from Santa Monica, CA 90401. For procurement directors, this necessitates immediate verification of existing inventory against the specified lot numbers and UPCs to prevent distribution of contaminated product. Regulatory affairs heads must ensure all reporting obligations to the FDA are met promptly, given the Class II classification indicates potential for temporary or medically reversible adverse health consequences. Supply chain VPs need to implement robust quarantine and return procedures for the 3,500 affected bottles, minimizing further exposure and ensuring compliance with regulatory mandates.

Critical Quality Control Failures: Implications for Benzoyl Peroxide Sourcing

The detection of benzene in Proactiv Skin Smoothing Exfoliator underscores a significant failure in quality control processes, particularly concerning raw material sourcing and manufacturing hygiene. Benzoyl Peroxide, the active ingredient, is a widely used topical agent, and its contamination with benzene presents a serious challenge for formulators across the dermatology and consumer health sectors. For procurement teams, this event demands an immediate and thorough re-evaluation of all suppliers providing Benzoyl Peroxide and related excipients. It is imperative to scrutinize Certificates of Analysis (CoAs) for comprehensive impurity profiles, specifically testing for benzene and other volatile organic compounds (VOCs), rather than relying solely on standard specifications. Supply chain VPs must revisit and strengthen quality agreements with contract manufacturing organizations (CMOs) and raw material vendors, ensuring that robust analytical testing methods are in place and routinely performed to detect unexpected contaminants. This incident highlights that even well-established active pharmaceutical ingredients (APIs) can carry inherent risks if supplier qualification and ongoing monitoring are not rigorously maintained. Business development executives should recognize the heightened scrutiny this event places on product safety and quality, potentially influencing consumer purchasing decisions and market share in the competitive topical drug market.

Navigating Regulatory Scrutiny and Market Repercussions for Topical Drug Products

The Class II classification of this recall by the FDA signals a serious health risk, prompting a heightened level of regulatory oversight. While Alchemee, LLC initiated this recall voluntarily, the FDA's involvement ensures that all necessary corrective actions are taken. For regulatory affairs heads, this means preparing for potential inquiries from the FDA regarding the root cause analysis, corrective and preventive actions (CAPAs), and the effectiveness of the recall. The voluntary nature of the recall, initiated via e-mail, indicates the firm's awareness and response, but the underlying issue of chemical contamination will likely lead to increased scrutiny of their manufacturing practices and quality management systems. Supply chain VPs must ensure that recall logistics are executed flawlessly to minimize further regulatory exposure and potential penalties. Beyond immediate compliance, the presence of benzene in a widely recognized consumer product like Proactiv carries significant reputational risks. Business development executives must anticipate potential erosion of consumer trust and brand loyalty, which can impact future sales and market positioning. This incident serves as a stark reminder for all industry players that robust quality assurance throughout the product lifecycle, from raw material to finished good, is paramount not only for regulatory compliance but also for sustaining market credibility and consumer confidence in topical drug products.

ChemLifeIntel analysis · Priya Subramaniam. Compiled from primary and reported sources.
CHEMLIFEINTEL TERMINAL

Go deeper than the brief

The Terminal adds the full entity graph behind this story — downstream buyer-exposure mapping, alternative-supplier shortlists, 5-year compliance footprints and live supply-chain risk scores. Built for procurement, regulatory and business-development teams.

TERMINAL ACCESS
Request Terminal Access

Tell us where to send your access details — covering 1,200+ pharmaceutical and chemical companies across the global value chain.

Covering 1,200+ pharmaceutical and chemical companies across the global value chain
CONNECTED COVERAGE

Related Intelligence

REGULATORY INTELLIGENCE
3d ago

CDSCO Enacts Sweeping Regulatory Changes Across India's Pharma and Medical Device Sectors

India's CDSCO has issued numerous critical regulatory updates, impacting drug formulations, medical devices, and animal health. These changes, including product restrictions, revised fees, and new import rules, necessitate immediate review by procurement, regulatory affairs, and supply chain leaders to maintain compliance and mitigate operational risks across the Indian market.

REGULATORY INTELLIGENCE
3d ago

ANSM Fines Novo Nordisk and Eli Lilly for GLP-1 Obesity Campaign Breaches, Novo Nordisk Explores Legal Challenge

France's ANSM has fined Novo Nordisk and Eli Lilly for obesity campaign breaches related to GLP-1 analogue misuse. This action underscores escalating regulatory scrutiny on high-demand drug marketing. Novo Nordisk is considering a legal challenge, signaling potential prolonged legal and reputational impacts for major pharmaceutical players in the European market.

REGULATORY INTELLIGENCE
4d ago

FDA Faces Pressure to Restrict Livestock Antibiotic Use: Major Commercial Implications for Chemical and Life Sciences

Over 60 organizations have petitioned the FDA to revoke approvals for antibiotic use in livestock for disease prevention and growth promotion. This action, driven by concerns over antibiotic resistance and its human health toll, signals potential significant regulatory shifts. Procurement, supply chain, and regulatory affairs leaders must prepare for market disruption and new compliance requirements.

REGULATORY INTELLIGENCE
4d ago

Germany Abandons Branded Pharmaceutical Price Reduction Plan Amid Industry Opposition

Germany has reversed its decision to implement a variable pricing structure aimed at reducing branded pharmaceutical costs, following significant criticism from drug manufacturers. This move signals a crucial win for pharmaceutical companies, preserving current revenue models and mitigating potential market access challenges in one of Europe's largest economies. Procurement and regulatory teams should reassess their German market strategies.

REGULATORY INTELLIGENCE
4d ago

Health Canada's Drug Product Database: A Critical Resource for Market Intelligence and Regulatory Compliance

Health Canada's Drug Product Database (DPD), last updated March 1, 2019, offers vital intelligence for market access and regulatory compliance. This comprehensive online tool allows stakeholders to query drug identification numbers (DINs), ATC codes, and company data. For procurement, regulatory, and business development executives, the DPD is indispensable for strategic planning and risk management within the Canadian pharmaceutical landscape.

REGULATORY INTELLIGENCE
4d ago

CDSCO Authorizes Oseltamivir Outlets: Clarifying India's Supply Channels for H1N1 Antivirals

India's CDSCO has published a list of authorized outlets for oseltamivir formulation, critical for H1N1 swine flu. This action clarifies legitimate supply channels for this Schedule X drug, signaling intensified regulatory oversight in India's pharmaceutical sector. Procurement and supply chain leaders must ensure compliance with these defined distribution networks to mitigate risks and maintain market access.

REGULATORY INTELLIGENCE
5d ago

Express Scripts, PCMA Challenge Tennessee's FAIR Rx Act: PBM Vertical Integration Under Threat

Express Scripts and the PCMA are challenging Tennessee's FAIR Rx Act, a law prohibiting PBMs from owning pharmacies and restricting mail-order services. This follows CVS Caremark's similar lawsuit. If upheld, the law, effective 2028, threatens to close PBM-affiliated pharmacies, disrupt national drug supply chains, and impede patient access, impacting hundreds of thousands. This legal battle signals escalating state-level pressure on PBM business models.

REGULATORY INTELLIGENCE
6d ago

SonoThera Secures $125M Series B Funding: No FDA Import Alert Information Available

The provided source text details SonoThera's successful $125 million Series B funding round, backed by major pharma entities. Crucially, the source contains no information regarding any FDA Import Alert, regulatory action, facility issues, or product detentions, making an analysis of such an event impossible based on the given data.

REGULATORY INTELLIGENCE
6d ago

FDA Class II Recall: Essential Wellness Pharma's Progesterone Injection Fails Sterility Assurance

Kalman Health & Wellness, Inc. dba Essential Wellness Pharma initiated a Class II recall for its Progesterone 100 mg/mL in Corn Oil Injection due to a critical lack of sterility assurance. This 2015 nationwide recall, terminated in 2017, stemmed from poor sterile production practices at its Peoria, IL facility. For procurement and regulatory leaders, this highlights the severe risks associated with compounded sterile preparations and underscores the imperative for rigorous supplier qualification and ongoing oversight in this sector.

REGULATORY INTELLIGENCE
6d ago

CDSCO Intensifies Regulatory Scrutiny: Implications for India's Pharma and MedTech Supply Chains

CDSCO's recent flurry of alerts, including drug theft, falsified medicines, and product recalls, signals heightened regulatory vigilance across India's pharmaceutical and medical device sectors. This demands robust supply chain security, stringent quality controls, and agile regulatory compliance from global and domestic players. Procurement, regulatory, and supply chain leaders must proactively adapt to mitigate risks and ensure market access.

REGULATORY INTELLIGENCE
6d ago

FDA Hearing Puts Amgen's Tavneos Market Future at Risk Amid Independent Data Review

Amgen faces a critical FDA hearing for its rare disease treatment, Tavneos, following an independent data review. This event could lead to market removal, demanding immediate risk assessment for procurement, supply chain, and regulatory teams. It underscores the FDA's intensified scrutiny on post-market data integrity and product efficacy.

REGULATORY INTELLIGENCE
6d ago

Takeda's TYK2 Inhibitor Victory Reshapes Plaque Psoriasis Market Dynamics

Takeda has secured a significant competitive advantage in the TYK2 inhibitor landscape, outperforming Bristol Myers Squibb’s Sotyktu. This victory positions Takeda strongly for its anticipated plaque psoriasis launch next year, signaling a material shift in market share and procurement strategies for dermatology portfolios. Decision-makers must reassess existing supply agreements and future market entrants.

ENTITY HUBS

Entities in this Brief

Alchemee
company hub
Open company hub